Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329979 | 0.89 | KIF11 (0.41) | KIF11TDP2MKNK1MKNK2HDAC2 | |
| SCHEMBL11357927 | 0.88 | FEN1 (0.39) | KIF11FEN1 | |
| SCHEMBL21856971 | 0.82 | KDM4E (0.42) | — | |
| SCHEMBL23916410 | 0.82 | KIF11 (0.44) | KIF11FEN1MKNK1MKNK2MAP4K4 | |
| SCHEMBL13298692 | 0.80 | KIF11 (0.41) | KIF11TDP2HDAC2MAP4K4 | |
| SCHEMBL704506 | 0.78 | GFER (0.47) | KIF11MKNK1MKNK2 | |
| SCHEMBL3584128 | 0.77 | IKBKB (0.43) | KIF11 | |
| SCHEMBL6771385 | 0.77 | MKNK1 (0.44) | MKNK1MKNK2MAP4K4 | |
| SCHEMBL6775919 | 0.76 | DHFR (0.42) | — | |
| SCHEMBL6781482 | 0.75 | CHEK1 (0.40) | HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696475-B2 | N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS | NEUROSEARCH A/S (DK) | 2004-02-24 | — | — | US | disclosed |
| EP-0977741-B1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| US-6297261-B1 | POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE | NEUROSEARCH A/S (DK) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNH2, KCNJ2 | KIF11 2445/4885TDP2 4150/4885FEN1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.